statistiche ricercatore

Continente	#
EU - Europa	536
AS - Asia	312
NA - Nord America	280
SA - Sud America	52
Continente sconosciuto - Info sul continente non disponibili	32
AF - Africa	7
Totale	1.219

Nazione	#
RU - Federazione Russa	262
US - Stati Uniti d'America	253
IT - Italia	146
SG - Singapore	130
CN - Cina	84
BR - Brasile	41
VN - Vietnam	29
DE - Germania	24
HK - Hong Kong	24
NL - Olanda	18
FI - Finlandia	17
FR - Francia	17
GB - Regno Unito	17
CA - Canada	16
JP - Giappone	10
BD - Bangladesh	8
MX - Messico	8
SE - Svezia	8
AR - Argentina	6
IE - Irlanda	5
IN - India	5
AT - Austria	4
PL - Polonia	4
IL - Israele	3
SA - Arabia Saudita	3
BE - Belgio	2
DK - Danimarca	2
ES - Italia	2
IQ - Iraq	2
LB - Libano	2
MA - Marocco	2
MK - Macedonia	2
UZ - Uzbekistan	2
VE - Venezuela	2
ZA - Sudafrica	2
AO - Angola	1
BB - Barbados	1
BG - Bulgaria	1
BN - Brunei Darussalam	1
CL - Cile	1
CO - Colombia	1
CR - Costa Rica	1
GY - Guiana	1
HU - Ungheria	1
ID - Indonesia	1
IR - Iran	1
JM - Giamaica	1
KE - Kenya	1
KH - Cambogia	1
KR - Corea	1
LT - Lituania	1
MY - Malesia	1
PH - Filippine	1
PK - Pakistan	1
QA - Qatar	1
SI - Slovenia	1
SK - Slovacchia (Repubblica Slovacca)	1
TN - Tunisia	1
TR - Turchia	1
UA - Ucraina	1
Totale	1.187

Nome	#
Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells	184
CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function	153
Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells	152
TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells	140
Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases	108
Harnessing CD39 for the Treatment of Colorectal Cancer and Liver Metastases by Engineered T Cells	107
Harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells	103
HARNESSING CD39 FOR THE TREATMENT OF COLORECTAL CANCER AND LIVER METASTASES BY ENGINEERED T CELLS	97
Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors	92
TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength	53
T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication	20
Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR	10
Totale	1.219

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	8	0	0	0	0	0	0	0	0	3	1	0	4
2022/2023	16	2	2	3	1	1	2	0	0	2	3	0	0
2023/2024	53	3	1	8	4	3	2	6	6	2	4	3	11
2024/2025	231	10	8	11	7	12	19	40	41	13	17	18	35
2025/2026	855	57	30	22	103	134	36	57	90	235	44	19	28
2026/2027	56	28	28	0	0	0	0	0	0	0	0	0	0
Totale													1.219